VEGFR2 cytoplasmic expression (VEGFR2ce) in relation to survival in metastatic breast cancer (MBC) patients (pts) treated with bevacizumab (Bev).

Roseana Melo Borba,Tiago Felismino,Alexandre Andre Balieiro Anastacio da Costa,Vladmir Cláudio Cordeiro de Lima,Marcelo Corassa,Stephania M. Bezerra,Cynthia Bueno de Toledo Osorio,Tadeu Ferreira Paiva

VEGFR2 cytoplasmic expression (VEGFR2ce) in relation to survival in metastatic breast cancer (MBC) patients (pts) treated with bevacizumab (Bev).

2017

Roseana Melo Borba
Tiago Felismino
Alexandre Andre Balieiro Anastacio da Costa
Vladmir Cláudio Cordeiro de Lima
Marcelo Corassa
Stephania M. Bezerra
Cynthia Bueno de Toledo Osorio
Tadeu Ferreira Paiva

11523Background: Bev is a monoclonal antibody that binds to VEGFA that demonstrated improved progression free survival (PFS) in MBC clinical trials. VEGFR2, NOTCH1, Integrin a1b2 and ILK are angiog...

Keywords:

Bevacizumab
VEGF receptors
Pathology
Medicine
Metastatic breast cancer
Cancer research
Cytoplasm
Integrin
Clinical trial
Progression-free survival
Vascular endothelial growth factor A
Monoclonal antibody

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations